(Public, NASDAQ:CPHD)   Watch this stock  
Find more results for CPHD
+0.43 (1.17%)
Nov 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 36.62 - 37.53
52 week 29.21 - 63.69
Open 36.79
Vol / Avg. 228,189.00/1.10M
Mkt cap 2.69B
P/E     -
Div/yield     -
EPS -0.87
Shares 72.34M
Beta 0.25
Inst. own 107%
Jan 27, 2016
Q4 2015 Cepheid Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Dec 1, 2015
Cepheid at Piper Jaffray Healthcare Conference - 11:00AM EST - Add to calendar
Oct 20, 2015
Q3 2015 Cepheid Earnings Call - Webcast
Oct 20, 2015
Q3 2015 Cepheid Earnings Release
Oct 13, 2015
Q3 2015 Cepheid Preliminary Results Call
Oct 13, 2015
Q3 2015 Cepheid Earnings Preliminary Results
Sep 10, 2015
Cepheid at Wells Fargo Healthcare Conference
Sep 9, 2015
Cepheid at Robert W Baird and Co Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -18.11% -10.67%
Operating margin -15.40% -7.25%
EBITD margin - 3.70%
Return on average assets -11.17% -8.44%
Return on average equity -24.78% -15.68%
Employees 1,400 -
CDP Score - -


904 Caribbean Drive
United States - Map
+1-408-5414191 (Phone)
+1-408-5414192 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the clinical market and non-clinical markets. Its systems enable molecular testing for organisms and genetic-based diseases. Molecular testing involves various time-intensive steps, including sample preparation, DNA amplification and detection. The Company’s systems integrate these steps and analyze biological samples in test cartridges. Its primary offering is the GeneXpert system, which integrates sample preparation in addition to DNA amplification and detection, serves reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals, as well as physician offices and other alternate site laboratories. It also offers the SmartCycler system, which integrates DNA amplification and detection to allow rapid analysis of a sample.

Officers and directors

John L. Bishop Chairman of the Board, Chief Executive Officer
Age: 70
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Daniel E. Madden Chief Financial Officer, Executive Vice President
Age: 47
Bio & Compensation  - Reuters
Warren C. Kocmond Jr. Chief Operating Officer, Principal Operating Officer, Executive Vice President
Age: 55
Bio & Compensation  - Reuters
David H. Persing M.D., Ph.D. Executive Vice President, Chief Medical and Technology Officer, Director
Bio & Compensation  - Reuters
Joseph H. Smith Executive Vice President - Corporate Development, General Counsel
Age: 70
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Peter Farrell Executive Vice President - International Commercial Operations
Age: 50
Bio & Compensation  - Reuters
Michael Fitzgerald Executive Vice President, Global Human Resources
Age: 55
Bio & Compensation  - Reuters
Kerry J. Flom Ph.D. Executive Vice President, Chief Regulatory Officer
Age: 63
Bio & Compensation  - Reuters
Cristina H. Kepner Lead Independent Director
Age: 69
Bio & Compensation  - Reuters
Thomas D. Brown Independent Director
Age: 67
Bio & Compensation  - Reuters